SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

Refixia

NVO·NOVO NORDISK A S
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed in the US (since 2017) and EU (since 2017).
Why 3/10
No hard dated catalyst (PDUFA, pivotal readout, or AdComm) is scheduled for Refixia/Rebinyn in the next 12 months. The drug is fully approved and commercialized in both the US and EU. It represents a small fraction of Novo Nordisk's overall value, which is overwhelmingly driven by GLP-1 diabetes/obesity products.
Actionable Insight NEUTRAL

Refixia/Rebinyn is a mature, approved product with no upcoming binary catalysts. Watch for quarterly Novo Nordisk rare disease segment revenue trends and any competitive developments from CSL's Hemgenix gene therapy or newer non-factor therapies like Mim8 (denecimig) that could shift the hemophilia B treatment landscape.

Price Chart

Loading chart...

Executive Summary

Refixia (nonacog beta pegol, sold as Rebinyn in the US) is an extended half-life recombinant factor IX replacement therapy for hemophilia B, developed and marketed by Novo Nordisk (NYSE: NVO). It was approved by the EMA in June 2017 and by the FDA in May 2017, with a subsequent FDA label expansion for routine prophylaxis in July 2022. The drug is fully commercialized in both major markets and competes in a crowded factor IX replacement market against other extended half-life products (Alprolix, Idelvion) and faces long-term disruption risk from gene therapy (Hemgenix). For Novo Nordisk, a company valued primarily on its GLP-1 franchise (Ozempic, Wegovy), Refixia is a small, mature rare-disease product with no upcoming binary catalysts.

How It Works

Refixia is a replacement therapy for hemophilia B, a genetic bleeding disorder where patients lack a functional blood-clotting protein called factor IX. The drug is a lab-made version of factor IX that has been chemically modified with a PEG molecule (a common pharmaceutical technique) to make it last longer in the body. When injected into a vein, it temporarily restores the missing clotting factor, allowing blood to clot normally. Patients use it either on-demand to stop bleeding episodes or as a weekly preventive (prophylaxis) to reduce the frequency of bleeds.

Trial Status

Refixia/Rebinyn was approved based on the Phase 3 Paradigm clinical program. Long-term follow-up studies (including 5-year pediatric data from Paradigm 5) have been completed, confirming sustained safety and efficacy. The drug is fully commercialized with no active pivotal trials seeking initial approval.

The Two-Sided Case

▲ Bull Case5
Extended half-life (glycoPEGylated) allows once-weekly prophylactic dosing versus 2-3 times weekly for standard FIX products, improving patient convenience.
Approved for both on-demand treatment and routine prophylaxis in adults and children across the US (as Rebinyn) and EU (as Refixia), covering the full hemophilia B treatment spectrum.
Long-term safety and efficacy data from the Paradigm clinical program, including 5-year pediatric data, support a well-established profile.
The global hemophilia B market is projected to grow at a CAGR of ~7-9%, driven by rising diagnosis rates and expanded access to prophylaxis.
Pfizer's exit from hemophilia B gene therapy (discontinued Beqvez in 2025) reduces one competitive threat to the factor replacement market.
▼ Bear Case5
Faces direct competition from other extended half-life FIX products including Alprolix (Sanofi) and Idelvion (CSL Behring), as well as standard half-life products like BeneFIX.
Gene therapy Hemgenix (CSL Behring) offers a one-time curative option that could shrink the addressable patient pool for chronic factor replacement over time.
Newer non-factor therapies such as Hympavzi (marstacimab) and Novo Nordisk's own investigational Mim8 (denecimig) could disrupt the factor replacement market.
As a small part of Novo Nordisk's massive GLP-1-dominated business, Refixia receives limited strategic focus and investor attention.
Payer pressure and formulary competition among multiple EHL FIX products may constrain pricing and revenue growth.

Upcoming Catalysts

  • No upcoming PDUFA dates, regulatory decisions, or pivotal readouts are scheduled for Refixia/Rebinyn in the next 12 months. The drug is a mature, approved product.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

NOVO NORDISK A S 6-K NVO ·Originating report

Sources · 12

Hover a chip for the title
1 ema.europa.eu2 fda.gov3 drugs.com4 fda.gov5 bleeding.org6 pharmacytimes.com7 hemophilianewstoday.com8 adisinsight.springer.com9 fiercepharma.com10 novomedlink.com11 prnewswire.com12 ema.europa.eu